Effect of Yiqi Fumai lyophilized injection on B-type natriuretic peptide levels in patients with acute decompensated ischemic heart failure: a multicenter, open-label, blinded-outcome, randomized controlled trial

What Was Tested

Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.

Patients with acute decompensated ischemic heart failure (ADIHF) often present with severe clinical symptoms and poor quality of life.

In China, Yiqi Fumai lyophilized injection (YQFM) is widely used in the treatment of ADIHF.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

By conducting a multicenter, open-label, blinded-outcome, randomized controlled trial, the researchers recruited patients with ADIHF from 37 hospitals in 20 regions of China from October 2015 to October 2018.

Patients were allocated in a 1:1 ratio to either the YQFM group or the control group.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when BNP (Nesiritide) was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Running at several centres spread the BNP (Nesiritide) study over different clinics and patient groups.

A time span of 7 days appears in the methods.

Both groups received guideline-directed medical therapy (GDMT), with the YQFM group additionally receiving YQFM for 7 days.

The researchers evaluated the left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) functional class, Minnesota Living with Heart Failure Questionnaire (MLHFQ) score, and composite endpoints.

What Was Measured

The subject headings attached to it are China, Drugs, Chinese Herbal, Freeze Drying, Heart Failure, Injections, Myocardial Ischemia and Natriuretic Peptide, Brain.

Author keywords: Acute decompensated ischemic heart failure, B-type natriuretic peptide, Randomized controlled trial, Traditional Chinese medicine and Yiqi Fumai lyophilized injection.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of BNP (Nesiritide) over 7 days.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Phytomedicine : international journal of phytotherapy and phytopharmacology), a journal based in Germany.

More context: the BNP (Nesiritide) compound page, all human trials.